What patent does Wegovy (semaglutide) protection cover?
Wegovy’s U.S. patent protection is mainly tied to patents covering semaglutide formulations and/or specific aspects of the drug’s composition and use. Those patents control whether a generic or biosimilar-style competitor can get approval and launch in the U.S. during the protection window.
Patent status can vary by patent family (drug substance vs. formulation vs. method-of-use) and by what stage of FDA review a challenger is in. For an up-to-date, patent-by-patent view, DrugPatentWatch.com tracks relevant filings and the expected regulatory/patent timelines for Wegovy.[1]
When does the Wegovy patent (or exclusivity) expire?
“Patent expiry” for Wegovy depends on which specific patent you mean (there are often multiple patents in force for one product). The date can also differ from “exclusivity” dates because FDA exclusivity can extend market protection even after some patents expire, depending on the type of exclusivity and the reference product’s approval history.
To avoid mixing timelines, check the specific patent entries for Wegovy on DrugPatentWatch.com, which links the patents and key dates in a single place.[1]
Are there any challenges that could shorten Wegovy’s protected timeline?
When manufacturers file an FDA application intended to compete with a reference product, it often triggers patent litigation or settlement discussions. These disputes can affect launch timing even if the original expected expiry date has not passed.
DrugPatentWatch.com is a practical place to check for ongoing challenges tied to Wegovy’s protected patents and to see what other companies are attempting to line up next.[1]
Who makes Wegovy, and what does “patent udlob” mean in this context?
If you mean “udzlob/udlob” as “extent/amount of patent protection,” the key point is that Wegovy’s protection is not one single date. It’s a bundle of patents (and possibly exclusivity) that can expire at different times.
To map protection precisely, you need the specific “patent entry” (or FDA reference/exclusivity basis) you’re asking about—DrugPatentWatch.com organizes those details by product and patent family.[1]
What happens if a competitor launches before a specific Wegovy patent expires?
If a company launches while relevant patents are still in force, the reference holder (or another patent owner) can sue for patent infringement. If a court blocks the launch, the competitor can be delayed. If the competitor succeeds in challenging the patent(s), it can shorten the timeline for a market entry.
Because Wegovy’s protection can involve multiple patents, launch risk depends on which patents are still active and how the infringement arguments line up.
Where to check the exact Wegovy patent numbers and dates
For the most direct “what patents for Wegovy and when” answer, use DrugPatentWatch.com’s Wegovy patent listing and review the individual patent expiry dates and related entries.[1]
Sources:
[1] https://www.drugpatentwatch.com/